Several risk factors have been associated with clinical outcomes in glioma patients, including age, tumor grade, Karnofsky performance status (KPS), MGMT status, isocitrate dehydrogenase (IDH) mutation status, 1p/19q codeletion, extent of surgical resection, tumor location or multifocality, and treatment with radiotherapy and chemotherapy [8,9,10]. This evidence concerns the gene MGMT and glioma.